Evidence Table 12Evidence profile of chronic kidney disease trials: Losartan compared with enalapril monotherapy

Summary of Findings
Quality AssessmentResults by study, Relative effectQuality of the evidence for each outcome
StudyDesignQualityInconsistencyIndirectnessImprecisionOther considerations
Changes in renal function-proteinuria
Renke 2004
n = 54
RCTFairConsistentDirectImpreciseOne trial did not provide statistical analysis between groups.NSD between groups.Low
Tylicki 2002
n = 51
RCTFairNSD between groups.
Tylicki 2005
n = 40
RCTFairNSD between groups.
Changes in renal function-creatinine clearance
Renke 2004
n = 54
RCTFairConsistentDirectImpreciseTwo of three trials only reported no significant change in CrCl from baseline; no analysis between groups.NSD between groups.Very Low
Tylicki 2002
n = 51
RCTFairNSD between groups.
Tylicki 2005
n = 40
RCTFairNSD between groups.
Overall withdrawals
Renke 2004
n = 54
RCTFairConsistentDirectImpreciseNSD between groups.Low
Tylicki 2002
n = 51
RCTFairNSD between groups.
Tylicki 2005
n = 40
RCTFairNSD between groups.

From: Evidence Tables

Cover of Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers
Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers: Final Report [Internet].
Norris S, Weinstein J, Peterson K, et al.
Portland (OR): Oregon Health & Science University; 2010 Jan.
Copyright © 2009, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.